Established in 2011, Ennogen is a pharmaceutical and healthcare company focused on reinvigorating heritage brands to meet underserved clinical need. The company operates across five key therapeutic areas: dermatology, respiratory, otology, blood pressure and pain relief – predominantly supporting patients with chronic conditions.

Headquartered in Dubai and offices in Dartford, Northwich, and Dublin, Ennogen has grown both organically and through acquisitions building an extensive portfolio of products and now employing more than 70 members of staff.

“We are pleased to have secured the support of a strong banking syndicate comprising Santander, Barclays, and HSBC. The £150m facility provides a flexible platform to support Ennogen’s growth strategy. This agreement strengthens our capacity to pursue acquisitions and invest further in our innovation pipeline as we continue to execute on our ambitious plans. Working with the syndicate’s teams in Manchester and Liverpool, it is clear they each have a strong understanding of Ennogen’s particular requirements within the pharmaceutical and healthcare industry.”

“We are delighted to continue to support Ennogen’s growth trajectory with a further round of funding. Ennogen has firmly established itself as a key player in UK Pharma ensuring core heritage products remain available and accessible. The business has continued to evidence strong and sustainable growth, both organically and via acquisition, with three such transactions completed under our bilateral facility put in place in 2024.  Ennogen is exactly the type of business Santander looks to support, with a strong management team, niche product suite and a clearly articulated strategy. We look forward to this next phase of growth, now supported by the £150m lending facility, as well as management’s plans for 2026 and beyond.”

“We are delighted to support Ennogen with a facility package that supports their next phase of growth. The business has gone from strength to strength and this upsized facility will provide headroom and flexibility to allow Ennogen to invest in their innovation pipeline and acquisition strategy. We are committed to helping businesses invest for growth and are pleased to see our £22bn Business Prosperity Fund in action through this package of lending.”

“It’s fantastic to support Ennogen Healthcare as part of this new syndicated financing facility. Ennogen’s long-term commitment to international expansion, combined with its focus on delivering innovation in new markets aligns with HSBC UK’s strategy of supporting ambitious businesses. We look forward to seeing Ennogen achieve its global growth potential.”

“We’re thrilled to have supported Ennogen on this milestone transaction. It’s been a remarkable journey watching their impressive growth over the past 5 years and we’re grateful to have played a part in it. Huge congratulations to John, Jason and the entire Ennogen team, we’re looking forward to seeing what the next 5 years will bring”.